Drug development and research in New Zealand

Policies affecting the industry

Michelle Marie Lockhart, Zaheer Ud Din Babar, Sanjay Garg

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Many countries employ a range of policies to support their drug development industry. The support is primarily because of the perceived potential benefits from wealth creation, employment, and international trade related to a high-technology industry. New Zealand (NZ) has a growing drug development industry; this article reports on the results of interviews with people representing the industry. The NZ industry reported that government policies that included funding of scientific, medical, and drug development research, a robust regulatory system, and strong patent laws have created a cluster of expertise for specialized drug development services. This is similar to those that have been reported to encourage the biotechnology industries of many countries. Threats to the industry in NZ include insufficient funding, small industry size, insufficient supportive policies, and stakeholders' lack of understanding of the industry. These barriers differ from those of developing countries such as China and India, probably because NZ's industry is built on its scientific and medical research rather than its manufacturing capability. The specific policies requested to further support the NZ industry include increased government investment, improved management of funding, and support for research, education, and career development.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalDrug Development Research
Volume73
Issue number1
Early online date27 Jul 2011
DOIs
Publication statusPublished - 1 Feb 2012
Externally publishedYes

Fingerprint

New Zealand
Industry
Research
Pharmaceutical Preparations
Drug Industry
Biotechnology
Developing Countries
Biomedical Research
India
China
Interviews
Technology
Education

Cite this

@article{ed2826c0901d487ab0e12ae13e241203,
title = "Drug development and research in New Zealand: Policies affecting the industry",
abstract = "Many countries employ a range of policies to support their drug development industry. The support is primarily because of the perceived potential benefits from wealth creation, employment, and international trade related to a high-technology industry. New Zealand (NZ) has a growing drug development industry; this article reports on the results of interviews with people representing the industry. The NZ industry reported that government policies that included funding of scientific, medical, and drug development research, a robust regulatory system, and strong patent laws have created a cluster of expertise for specialized drug development services. This is similar to those that have been reported to encourage the biotechnology industries of many countries. Threats to the industry in NZ include insufficient funding, small industry size, insufficient supportive policies, and stakeholders' lack of understanding of the industry. These barriers differ from those of developing countries such as China and India, probably because NZ's industry is built on its scientific and medical research rather than its manufacturing capability. The specific policies requested to further support the NZ industry include increased government investment, improved management of funding, and support for research, education, and career development.",
keywords = "Drug development, Innovation, Policy, Qualitative, Research and development",
author = "Lockhart, {Michelle Marie} and Babar, {Zaheer Ud Din} and Sanjay Garg",
year = "2012",
month = "2",
day = "1",
doi = "10.1002/ddr.20460",
language = "English",
volume = "73",
pages = "1--10",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Drug development and research in New Zealand : Policies affecting the industry. / Lockhart, Michelle Marie; Babar, Zaheer Ud Din; Garg, Sanjay.

In: Drug Development Research, Vol. 73, No. 1, 01.02.2012, p. 1-10.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Drug development and research in New Zealand

T2 - Policies affecting the industry

AU - Lockhart, Michelle Marie

AU - Babar, Zaheer Ud Din

AU - Garg, Sanjay

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Many countries employ a range of policies to support their drug development industry. The support is primarily because of the perceived potential benefits from wealth creation, employment, and international trade related to a high-technology industry. New Zealand (NZ) has a growing drug development industry; this article reports on the results of interviews with people representing the industry. The NZ industry reported that government policies that included funding of scientific, medical, and drug development research, a robust regulatory system, and strong patent laws have created a cluster of expertise for specialized drug development services. This is similar to those that have been reported to encourage the biotechnology industries of many countries. Threats to the industry in NZ include insufficient funding, small industry size, insufficient supportive policies, and stakeholders' lack of understanding of the industry. These barriers differ from those of developing countries such as China and India, probably because NZ's industry is built on its scientific and medical research rather than its manufacturing capability. The specific policies requested to further support the NZ industry include increased government investment, improved management of funding, and support for research, education, and career development.

AB - Many countries employ a range of policies to support their drug development industry. The support is primarily because of the perceived potential benefits from wealth creation, employment, and international trade related to a high-technology industry. New Zealand (NZ) has a growing drug development industry; this article reports on the results of interviews with people representing the industry. The NZ industry reported that government policies that included funding of scientific, medical, and drug development research, a robust regulatory system, and strong patent laws have created a cluster of expertise for specialized drug development services. This is similar to those that have been reported to encourage the biotechnology industries of many countries. Threats to the industry in NZ include insufficient funding, small industry size, insufficient supportive policies, and stakeholders' lack of understanding of the industry. These barriers differ from those of developing countries such as China and India, probably because NZ's industry is built on its scientific and medical research rather than its manufacturing capability. The specific policies requested to further support the NZ industry include increased government investment, improved management of funding, and support for research, education, and career development.

KW - Drug development

KW - Innovation

KW - Policy

KW - Qualitative

KW - Research and development

UR - http://www.scopus.com/inward/record.url?scp=84858709180&partnerID=8YFLogxK

U2 - 10.1002/ddr.20460

DO - 10.1002/ddr.20460

M3 - Review article

VL - 73

SP - 1

EP - 10

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 1

ER -